Signaling Update contents for 23 January 2009

	Signaling Update — 23 January 2009 Signaling Update is a one-stop online resource designed to keep you in touch with the latest and most exciting research in cell signaling. New content is uploaded every Friday.
	New in Signaling Update this week:
	featured article  Cytokinesis: Rho activity in flux The GTPase activating protein MgcRacGAP is required throughout cytokinesis to regulate the spatiotemporal activation of Rho. Original paper: Nature Cell Biology 11, 71-77 (2009) previous featured articles molecule pages  The Molecule Pages A comprehensive, relational, signaling database. Each week we highlight an expert-authored, peer-reviewed Molecule Page. CD150 CD150 is a type I glycoprotein belonging to the CD2/CD150 family of the immunoglobulin superfamily of proteins. CD150 is a low-affinity self-ligand and also serves as a receptor for viruses such as measles, canine distemper and rinderpest. CD150 is involved in the regulation of differentiation and/or function of T helper (TH) 1 and TH2 cells, B lymphocytes, innate-like lymphocytes, dendritic cells and macrophages. search the molecule pages selected updates  Allergy: Allergic mimicry The main house dust mite allergen acts as a functional homologue of the Toll-like receptor 4 (TLR4) signaling co-factor MD2 to drive airway inflammation in a TLR4-dependent manner. Original research paper: Nature advance online publication 7 December 2008 (10.1038/nature07548) Cell polarity: Morphogenesis is the key Loss of the cell polarity protein scribble (SCRIB) cooperates with oncogenic MYC to drive the transformation of mammary epithelial cells. Original research paper: Cell 135, 865-878 (2008) Anticancer drugs: Targeting triple-negative breast cancer Inhibitors of poly(ADP-ribose) polymerase 1 (PARP1), an enzyme that has a key role in DNA repair, show promise for treating hormone-receptor-positive and ERBB2-overexpressing breast cancers. Original research paper: Proc. Natl Acad. Sci. USA 105, 17079-17084 (2008) more updates research library  The Research Library brings together all recent signaling-related research published in the Nature Publishing Group journals. Divided up into subject categories or by date, you can be guaranteed to find what you are looking for. Here is a selection of the newest and hottest research published this week. The nature of the globular- to fibrous-actin transition Nature 457, 441-445 (2009) Subscribe to this journal Proteolysis of NF-κB1 p105 is essential for T cell antigen receptor–induced proliferation Nature Immunology 10, 38-47 (2009) Subscribe to this journal Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects Nature Chemical Biology 5, 37-44 (2009) Subscribe to this journal signaling news  Nature Insight: RNA silencing In the past decade, the idea that RNA is just a passive carrier of information has been overturned. Small non-coding RNA molecules are now known to be important regulators of gene expression and genome integrity. This Nature Insight on RNA silencing presents a series of FREE review articles on this rapidly evolving field. more news gateway updates  PSI-Nature Structural Genomics Knowledgebase - January Update The Structural Genomics Knowledgebase is a free portal to research data and other resources from the Protein Structure Initiative for structural biologists to keep informed of the latest developments in their field. This month's update features articles on a new class of E3 ubiquitination enzymes, poly(A) RNA recognition and imidazolonepropionase (HutI). Sign up to receive monthly updates from the PSI-Nature Structural Genomics Knowledgebase job of the week  from naturejobs the scientific careers resource Postdoctoral Research Fellow Employer: MGH/Harvard Medical School Location: Boston, MA, USA A postdoctoral position is available in Dr. Lee Zou’s laboratory at the Massachusetts General Hospital Cancer Center and Harvard Medical School. The successful applicant will explore how DNA damage checkpoint signaling is regulated by epigenetic mechanisms, novel protein modifications and targeted protein degradation and investigate how the checkpoint can be exploited in targeted cancer therapy. more jobs To advertise a job in this spot, please contact Naturejobs.
	Genentech is proud to be a corporate sponsor of the UCSD-Nature Signaling Gateway. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Fifteen of the currently approved biotechnology products stem from or are based on Genentech science. Genentech manufactures and commercializes ten biotechnology products directly in the United States. The company has headquarters in South San Francisco, California, and is traded on the New York Stock Exchange under the symbol DNA. www.biooncology.com As a registered user of the Nature Publishing Group web sites, you were selected to receive this message in the genuine belief that it would be of interest to you. If you no longer wish to receive news and announcements from Nature Publishing Group or wish to unsubscribe from the Signaling Update email alert please update your online Nature.com account details here. For further technical assistance or any other enquiries, please click here. Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne - San Diego - San Francisco - Washington - New York - Boston © 2009 Nature Publishing Group Privacy Policy